Matches in SemOpenAlex for { <https://semopenalex.org/work/W137603156> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W137603156 endingPage "9" @default.
- W137603156 startingPage "1423" @default.
- W137603156 abstract "The FDA guidelines, recommending a trough/peak blood pressure response ratio of at least 50%, were formulated with a view to providing a definitive index of duration of action of an antihypertensive drug. The aim was to prevent the use of drug regimens that utilised high doses of drug with the aim of maintaining a significant reduction in blood pressure at the end of the steady state dosage interval. The calculation of trough/peak ratios is subject to significant variability but much of this can be directly attributed to different methodological approaches. However, when conditions are standardised it has been shown that trough/peak ratios are reproducible in individual patients. Trough/peak ratios defined for different antihypertensive drugs often exhibit as many differences within a therapeutic class as between therapeutic classes. Thus there is no single therapeutic class of drugs that offers high trough/peak ratios compared to an alternative class. The possible exception to this are the diuretics which probably all have comparatively high trough/peak ratios although this has never formally been defined. With respect to the beta adrenoceptor antagonists there is discernible discrimination between the once a day agents with betaxolol, bisoprolol and acebutolol all having a longer duration of action as defined by a higher trough/peak response than atenolol. Calcium antagonists show considerable variability in trough/peak ratio between different drugs. In particular the first generation agents, verapamil, nifedipine and diltiazem all had relatively low values. Not all the second generation agents were superior to this and at present only amlodipine and lacidipine and some of the reformulated agents meet the recommendations of the Guidelines for once a day drugs.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W137603156 created "2016-06-24" @default.
- W137603156 creator A5063277464 @default.
- W137603156 date "1994-11-01" @default.
- W137603156 modified "2023-09-27" @default.
- W137603156 title "New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses." @default.
- W137603156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7771888" @default.
- W137603156 hasPublicationYear "1994" @default.
- W137603156 type Work @default.
- W137603156 sameAs 137603156 @default.
- W137603156 citedByCount "3" @default.
- W137603156 countsByYear W1376031562020 @default.
- W137603156 crossrefType "journal-article" @default.
- W137603156 hasAuthorship W137603156A5063277464 @default.
- W137603156 hasConcept C112705442 @default.
- W137603156 hasConcept C126322002 @default.
- W137603156 hasConcept C139719470 @default.
- W137603156 hasConcept C141071460 @default.
- W137603156 hasConcept C162324750 @default.
- W137603156 hasConcept C164705383 @default.
- W137603156 hasConcept C19831878 @default.
- W137603156 hasConcept C2776525901 @default.
- W137603156 hasConcept C2776741139 @default.
- W137603156 hasConcept C2777022698 @default.
- W137603156 hasConcept C2778073030 @default.
- W137603156 hasConcept C2778679995 @default.
- W137603156 hasConcept C2779066535 @default.
- W137603156 hasConcept C2779670145 @default.
- W137603156 hasConcept C2779938033 @default.
- W137603156 hasConcept C2780035454 @default.
- W137603156 hasConcept C2781092963 @default.
- W137603156 hasConcept C2910800852 @default.
- W137603156 hasConcept C32239851 @default.
- W137603156 hasConcept C519063684 @default.
- W137603156 hasConcept C71924100 @default.
- W137603156 hasConcept C84393581 @default.
- W137603156 hasConcept C98274493 @default.
- W137603156 hasConceptScore W137603156C112705442 @default.
- W137603156 hasConceptScore W137603156C126322002 @default.
- W137603156 hasConceptScore W137603156C139719470 @default.
- W137603156 hasConceptScore W137603156C141071460 @default.
- W137603156 hasConceptScore W137603156C162324750 @default.
- W137603156 hasConceptScore W137603156C164705383 @default.
- W137603156 hasConceptScore W137603156C19831878 @default.
- W137603156 hasConceptScore W137603156C2776525901 @default.
- W137603156 hasConceptScore W137603156C2776741139 @default.
- W137603156 hasConceptScore W137603156C2777022698 @default.
- W137603156 hasConceptScore W137603156C2778073030 @default.
- W137603156 hasConceptScore W137603156C2778679995 @default.
- W137603156 hasConceptScore W137603156C2779066535 @default.
- W137603156 hasConceptScore W137603156C2779670145 @default.
- W137603156 hasConceptScore W137603156C2779938033 @default.
- W137603156 hasConceptScore W137603156C2780035454 @default.
- W137603156 hasConceptScore W137603156C2781092963 @default.
- W137603156 hasConceptScore W137603156C2910800852 @default.
- W137603156 hasConceptScore W137603156C32239851 @default.
- W137603156 hasConceptScore W137603156C519063684 @default.
- W137603156 hasConceptScore W137603156C71924100 @default.
- W137603156 hasConceptScore W137603156C84393581 @default.
- W137603156 hasConceptScore W137603156C98274493 @default.
- W137603156 hasIssue "11" @default.
- W137603156 hasLocation W1376031561 @default.
- W137603156 hasOpenAccess W137603156 @default.
- W137603156 hasPrimaryLocation W1376031561 @default.
- W137603156 hasRelatedWork W105593417 @default.
- W137603156 hasRelatedWork W137603156 @default.
- W137603156 hasRelatedWork W1964998296 @default.
- W137603156 hasRelatedWork W1981327374 @default.
- W137603156 hasRelatedWork W2054911035 @default.
- W137603156 hasRelatedWork W2155394692 @default.
- W137603156 hasRelatedWork W2395440452 @default.
- W137603156 hasRelatedWork W2411666116 @default.
- W137603156 hasRelatedWork W2411891299 @default.
- W137603156 hasRelatedWork W2796581368 @default.
- W137603156 hasVolume "87" @default.
- W137603156 isParatext "false" @default.
- W137603156 isRetracted "false" @default.
- W137603156 magId "137603156" @default.
- W137603156 workType "article" @default.